AB
Abbott Laboratories
ABT · NYSE
$105.25 -0.26% (-$0.27)
1M -0.27%
Market Cap $182.7B
P/E Ratio 33.67x
Div. Yield 2.35%
ROE 10.52%
Bulios Fair Price
$72.18
31.4% downside
Current Price
$105.25
Undervalued Fair Value Overvalued
According to Bulios Fair Price, ABT is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
5/9Valuation
40 /100
Fair EV/EBITDA 21.14x
P/S 3.92x
P/B 3.57x
Growth
27 /100
Declining Rev. growth 0.51%
FCF growth 1.78%
Book val. growth 12.42%
Profitability
86 /100
Strong Net margin 11.65%
Op. margin 17.03%
FCF margin 18.72%
Quality
40 /100
Average ROE 10.52%
ROA 4.97%
Asset turnover 0.43x
Debt
68 /100
Low Current ratio 1.38x
Int. coverage 12.56x
Net debt/EBITDA 2.77x
Stability
69 /100
Stable Rev. volatility 7.67%
EPS volatility 98.26%
Profitable years 6
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about ABT
Online
Sector
Healthcare
Industry
Medical - Devices
CEO
Robert Ford
Employees
115,000
Headquarters
Abbott Park
Upcoming events
21 OCT
Earnings
Upcoming earnings report